

Transforming Metastatic Breast Cancer Management

# Harnessing the Power of Antibody-Drug Conjugate Therapies

Live Symposium • May 31, 2024 • 6:30–8:00 PM CT

Hilton Chicago • Boulevard Room • 2nd Floor • Dinner at 6 PM CT



## Transforming Metastatic Breast Cancer Management

# Harnessing the Power of Antibody-Drug Conjugate Therapies

Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment options more acutely, leading to greater outcomes disparities. Antibody-drug conjugates (ADCs) are novel agents that may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether.

This 90-minute live activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

## Learning Objectives

**At the conclusion of this activity, learners will be able to better:**

- Integrate the latest data on ADCs to individualize treatment for mBC based on recent clinical evidence and updated guidelines
- Develop strategies for the management of AEs associated with ADCs used to treat patients with mBC
- Implement strategies to mitigate BC health disparities based on specific drivers of inequity

## Target Audience

Academic and community oncologists, nurse practitioners (NPs), physician associates (PAs), oncology pharmacists, and oncology nurses.

## Financial Support

Supported through an independent educational grant from Gilead Sciences, Inc.

## Faculty

### Hope S. Rugo, MD, FASCO (Moderator)

Professor of Medicine

Winterhof Family Professor of Breast Cancer

Director, Breast Oncology and Clinical Trials Education

Medical Director, Cancer Infusion Services

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California

### Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP

Genitourinary Medical Oncology

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey

### Lee S. Schwartzberg, MD, FACP

Chief, Medical Oncology and Hematology

Renown Health–Pennington Cancer Institute

Professor of Clinical Medicine

University of Nevada–Reno

Reno, Nevada

## Patient/Patient Advocate

### Deltra James

MBC Advocate and Death Doula

# Harnessing the Power of Antibody-Drug Conjugate Therapies

## Credit Information

### JOINTLY ACCREDITED PROVIDER



In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### IPCE CREDIT



This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.

### PHYSICIANS (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### PHARMACISTS (ACPE)

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007101-0000-24-001-L01-P).

### NURSES (ANCC)

This activity is designated for 1.5 contact hours.

Note to Nurse Practitioners: the content of this CNE activity pertains to Pharmacology.

### ONCOLOGY NURSING CERTIFICATION (ONCC)

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

**OCN**<sup>®</sup>—Oncology Nursing Practice (Scientific Basis/ Profession), Symptom Management & Palliative Care, Psychosocial Dimensions of Care

**AOCNP**<sup>®</sup>/**AOCNS**<sup>®</sup>—Cancer Treatment, Side Effect & Symptom Management, Professional Practice

**CPHON**<sup>®</sup>—Cancer Treatment, Side Effect & Symptom Management

**BMTCN**<sup>®</sup>—Professional Performance

**CBCN**<sup>®</sup>—Diagnosis & Staging, Nursing Practice (Symptom Management, EoL Care, Professional)

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

### PAS (AAPA)



Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME

Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

### ROYAL COLLEGE MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

### ABIM MOC



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### MIPS IMPROVEMENT ACTIVITY



Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA\_PSPA\_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.



# Harnessing the Power of Antibody-Drug Conjugate Therapies

## Faculty



### **Hope S. Rugo, MD, FASCO** (Moderator)

Hope S. Rugo, MD, FASCO, is a professor of medicine in the Division of Hematology/Oncology at the University of California–San Francisco (UCSF). She is the director of Breast Oncology and Clinical Trials Education at UCSF’s Helen Diller Family Comprehensive Cancer Center. Dr. Rugo is an internationally recognized expert in breast cancer. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating tumor DNA as a marker of response and resistance to therapy, neoadjuvant therapy, and safety/supportive care.

Dr. Rugo is a principal investigator of multiple clinical trials and has published widely in medical journals. She also plays an active role in the Alliance for Clinical Trials in Oncology, the Translational Breast Cancer Research Consortium (TBCRC), the American Society of Clinical Oncology (ASCO), and the Multinational Association of Supportive Care in Cancer (MASCC), as well as on international guideline committees, including the National Comprehensive Cancer Network (NCCN). Dr. Rugo is dedicated to education and mentorship, providing guidance to medical students, residents, and fellows at UCSF and beyond.



### **Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN**

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN, has more than 20 years of cumulative oncology experience. She stumbled into oncology by chance and was incredibly inspired to pursue a career in the field. Her nursing experience includes medical oncology in community, inpatient, and outpatient settings. She initially joined Rutgers Cancer Institute as a nurse clinician in adult infusion before transferring to the Stacy Goldstein Breast Cancer Center. Upon graduating from the nurse practitioner program at Drexel University, she joined the GU Medical Oncology group at Rutgers Cancer Institute.

The most gratifying part of Ms. Kota’s job is daily interaction with her patients as she accompanies them along their stressful journey. She thrives in an environment that promotes constant learning and loves to see things from a “big picture” perspective, while integrating the various aspects of cancer care into her daily practice.

# Harnessing the Power of Antibody-Drug Conjugate Therapies

## Faculty



### Lee S. Schwartzberg, MD, FACP

Lee Schwartzberg, MD, is the chief of Medical Oncology and Hematology for Renown Health–William N. Pennington Cancer Institute and is a professor of clinical medicine at the University of Nevada–Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades as the medical director at West Cancer Center & Research Institute. He was the division chief for hematology/oncology and a professor of medicine at the University of Tennessee Health Science Center from 2012–2017. He then served as the founding chief medical officer of OneOncology, a national oncology practice management company, through 2021. Previously, he served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated on several guideline committees, including breast cancer. Dr. Schwartzberg has published more than 300 peer-reviewed manuscripts, book chapters, and monographs, and is the founding editor in chief of the Elsevier website PracticeUpdate Oncology and the journal *Community Oncology*. His research interests focus on breast cancer, supportive care, precision medicine, and patient reported outcomes, and he maintains a clinical practice in breast cancer.

## Patient/Patient Advocate



### Deltra James

Deltra James is a New England–based mother, poet, and patient advocate. After being diagnosed at age 33 with triple-negative breast cancer that had already spread to her liver, she sought community through story sharing and creativity. Beginning as a member of the For the Breast of Us inaugural class of Baddie Ambassadors, she found her footing in the advocacy and cancer communities. Since then, she has joined forces with organizations—such as TOUCH, The Black Breast Cancer Alliance (BBCA); Project Life; Bright Spot Network; and Cactus Cancer Society—to support others in connecting with resources that aid in areas she is passionate about: mental wellness, therapeutic creative expression, parenting, divorce after diagnosis, and disparities due to income and race. Ms. James has lent her voice and experience to podcasts, including *Our MBC Life*, and on panels for organizations such as Infinite Strength and SHARE. After taking notice of rampant death anxiety within the cancer community, she ventured into deathcare work as a death doula to assist fellow patients in accomplishing necessary end-of-life planning while addressing fears.

# Harnessing the Power of Antibody-Drug Conjugate Therapies

## Disclosure Declarations

It is the policy of Creative Educational Concepts LLC (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company.

**Dr. Rugo** reports the following financial relationships:

- Consultant: Daiichi Sankyo, Inc.; Eisai Inc.; Mylan/Viatrix Inc.; and NAPO Therapeutics
- Grants: Ambrx; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; and Stemline Therapeutics, Inc.
- Research Support: (all payments to UC Regents) Ambrx; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; and Stemline Therapeutics, Inc.

**Ms. Kota** reports no financial relationships to disclose.

**Dr. Schwartzberg** reports the following financial relationships:

- Advisory Board: Coherus BioSciences; Foundation Medicine, Inc.; and Helsinn
- Consultant: AstraZeneca; Daiichi Sankyo, Inc.; GSK; and Seagen Inc.
- Speakers Bureau: AstraZeneca; Foundation Medicine, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.

**Ms. James** reports no financial relationships to disclose.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA). The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

The following individuals have no financial relationships to disclose:

- Alaa Bawaneh, MD, PhD (Peer Reviewer)
- Albert Eubanks, Jr., RN (Peer Reviewer)
- Nichole Lainhart (Planning Committee)
- David Modrak, PhD (Planning Committee)
- Sandra Caballero, PharmD (Planning Committee)
- Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
- Sharon Tordoff (Planning Committee)

# Harnessing the Power of Antibody-Drug Conjugate Therapies

## Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty.

### ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

### VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

## Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



## Downloadable Resources

Downloadable resources will be available at:  
[www.ceconcepts.com/MBCresources](http://www.ceconcepts.com/MBCresources)

## Engage with Us

Follow us @creative.educational.concepts for announcements about upcoming CME opportunities, healthcare news, and more!

